SciELO - Scientific Electronic Library Online

 
vol.130 issue4Disposable surgical face masks for preventing surgical wound infection in clean surgery author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Sao Paulo Medical Journal

Print version ISSN 1516-3180

Sao Paulo Med. J. vol.130 no.4 São Paulo  2012

http://dx.doi.org/10.1590/S1516-31802012000400015 

COCHRANE HIGHLIGHTS

 

Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents

 

 

Zbys Fedorowicz; Vanitha A. Jagannath; Ben Carter

 

 


ABSTRACT

BACKGROUND: Vomiting is a common manifestation of acute gastroenteritis in children and adolescents. When untreated, it can be a hindrance to oral rehydration therapy, which is the cornerstone in the management of acute gastroenteritis. Evidence is needed concerning the safety and efficacy of antiemetic use for vomiting in acute gastroenteritis in children.
OBJECTIVES: To assess the safety and effectiveness of antiemetics on gastroenteritis induced vomiting in children and adolescents.
SEARCH STRATEGY: We searched the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Trials Register comprising references identified from comprehensive electronic database searches and hand searches of relevant journals and abstract books of conferences. The search was re-run and is up to date as on 20 July 2010.
SELECTION CRITERIA: Randomized controlled trials comparing antiemetics with placebo or no treatment, in children and adolescents under the age of 18, for vomiting due to gastroenteritis.
DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data.
MAIN RESULTS: We included seven trials involving 1,020 participants. Mean time to cessation of vomiting in one study was 0.34 days less with dimenhydrinate suppository compared to placebo (P value = 0.036). Pooled data from three studies comparing oral ondansetron with placebo showed: a reduction in the immediate hospital admission rate (RR 0.40, NNT 17, 95% CI 10 to 100) but no difference between the hospitalization rates at 72 hours after discharge from the Emergency Department (ED); a reduction in IV rehydration rates both during the ED stay (RR 0.41, NNT 5, 95% CI 4 to 8), and in follow-up to 72 hours after discharge from the ED stay (worst-best scenario for ondansetron RR 0.57, NNT 6, 95% CI 4 to 13) and an increase in the proportion of patients with cessation of vomiting (RR 1.34, NNT 5, 95% CI 3 to 7). No significant difference was noted in the revisit rates or adverse events, although diarrhea was reported as a side effect in four of the five ondansetron studies. In one study the proportion of patients with cessation of vomiting in 24 hours was (58%) with IV ondansetron, (17%) placebo and (33%) in the metoclopramide group (P value = 0.039).
AUTHORS' CONCLUSIONS: Oral ondansetron increased the proportion of patients who had ceased vomiting and reduced the number needing intravenous rehydration and immediate hospital admission. Intravenous ondansetron and metoclopramide reduced the number of episodes of vomiting and hospital admission, and dimenhydrinate as a suppository reduced the duration of vomiting.


 

 

This is the abstract of a Cochrane Review published in the Cochrane Database of Systematic Reviews (CDSR) 2011, Issue 9, Art. No.: CD005506. DOI: 10.1002/14651858.CD005506.pub5 (http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005506.pub5/abstract). For full citation and authors' details see reference 1.

The full text is freely available from: http://www.cochranejournalclub.com/antiemetics-reducing-vomiting-related-acute-gastroenteritis-c/pdf/CD005506.pdf

 

REFERENCE

1. Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2011;(9):CD005506.         [ Links ]

 

COMMENTS

Bacterial and viral gastroenteritis are common in children and adolescents. Oral rehydration therapy (ORT) is one of the cornerstones for its treatment. Many pediatricians recommend that antiemetics should only be introduced to treat vomiting if this condition is preventing proper implementation of ORT. In Brazil, remarkably few studies have investigated the action of antiemetics,1,2 particularly in relation to gastroenteritis. This review compared the efficacy of various antiemetic drugs versus placebo or no treatment in cases of acute vomiting due to gastroenteritis among children and adolescents.

Seven published studies fulfilling the review inclusion criteria were taken into consideration, with a total of 1020 patients. The authors indicate that these seven studies had an uncertain or high risk of bias, thus prompting the need for caution when extrapolating the results to clinical practice. Among the outcomes studied, the time taken for cessation of vomiting was 34% lower in a study comparing dimenhydrinate suppositories with placebo. Data from three studies comparing oral ondansetron with placebo showed that there was reduction in the rate of immediate hospital admission (number needed to treat, NNT, of 17), reduced the need for intravenous hydration during the stay in the emergency room (NNT 5) and 72 hours after discharge (NNT 6), and increase in the proportion of patients with cessation of vomiting (NNT 5). Although the review showed that ondansetron presented a reasonable advantage, particularly for avoiding the need for intravenous hydration and cessation of vomiting, there is a need for further studies, especially in relation to  cost-benefit and cost-effectiveness, in order to obtain a broader view of the usefulness of these antiemetics in treating vomiting in cases of acute gastroenteritis.

 

REFERENCES

1. Luisi FA, Petrilli AS, Tanaka C, Caran EM. Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J. 2006;124(2):61-5.         [ Links ]

2. Lajolo PP, del Giglio A. Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials. Support Care Cancer. 2007;15(3):343-6.         [ Links ]

 

 

The independent commentary was written by Wilson Roberto Catapani 
Wilson Roberto Catapani. Titular Professor and Head of the Gastroenterology Department, Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil.